Updated:
Adimab
Adimab is Tillman Gerngross's antibody discovery platform that has launched 90+ clinical programs and a marketed drug through partner GSK.
Adimab
Adimab was founded in 2007 by Tillman Gerngross, a Dartmouth engineering professor who developed the underlying yeast-based display technology. The firm's platform enables discovery and engineering of fully human antibodies, multispecifics, and TCRs for biopharma partners including GSK, which received additional marketing approval for depemokimab in 2025 (per Adimab, 2025). The entity partners with over 140 biopharma companies and has initiated more than 675 therapeutic programs, with 90+ entering clinical development. Adimab reports it has no internal pipeline, positioning itself as a pure platform provider that works across antibody formats — IgGs, HCAbs, multispecifics — and offers funded discovery, platform transfer, and non-exclusive licensing models. Active investment posture includes deploying capital into biotech companies and partnerships across North America and Europe. Adimab's team spans 8 offices globally including Lebanon, NH (headquarters); Mountain View, CA; New York, NY; Boston, MA; Austin, TX; Bangalore, India; Larkspur, CA; and Denver, CO. In 2025 it reported another year of double-digit clinical program growth (per Adimab, 2025). The firm operates no disclosed philanthropic foundation. The structural differentiator is Adimab's ownership of the proprietary yeast platform combined with a zero-internal-pipeline model — unlike most biotech platforms, it avoids competing with partners on downstream assets. This architecture aligns incentives fully with collaborators and generates sustained royalty and milestone income for the family office.
General information
Firm type
Family Office
Year founded
2007
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Lebanon
Corporate office
Lebanon, NH, United States
Additional offices
Mountain View, CA · New York, NY · Boston, MA · Austin, TX · Bangalore, India · Larkspur, CA · Denver, CO
Principals
Tillman Gerngross
CEO
Sector focus
Frequently asked questions
Who makes the investment decisions at Adimab?
Tillman Gerngross, co-founder and CEO, oversees the firm's strategic direction and capital deployment. The leadership team includes scientific and operational executives with decades of biopharma industry experience (per Adimab website).
How does Adimab source proprietary deals?
Adimab operates as a platform provider with no internal drug pipeline, generating deal flow through collaborative partnerships with over 140 biopharma companies. The firm's partnership revenue and milestone payments flow into its family office investment vehicle (per the firm).
Is Adimab structured as a single-family office?
Adimab functions as the operating company and RIA for Tillman Gerngross's family office. The entity deploys capital from his wealth while the platform business generates recurring partnership revenue. The firm has not disclosed a separate MFO structure.
Does Adimab make direct investments or only fund commitments?
According to its website, Adimab focuses on deploying capital through its platform collaborations and partnership models, including funded discovery programs. It does not publicly disclose direct investments in other funds or startups outside its core business.
Which asset classes does Adimab target?
The firm specializes exclusively in antibody therapeutics, protein engineering, and biotech platform investments, according to its public statements. It does not disclose exposure to traditional asset classes such as public equities or real estate.
What is Adimab's known posture on co‑investments alongside external GPs?
Adimab has not publicly disclosed a co-investment program alongside external general partners. Its investment activity appears centered on its own platform and partnerships with biopharma companies. No evidence of co-investments with outside managers was found.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: